Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05292742
What this trial is testing

Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

Who this might be right for
Breast CancerAdjuvant Therapy
Fujian Medical University Union Hospital 206
Large-scale testing (Phase 3)Looking for participantsNCT03561740
What this trial is testing

The Addition of Metronomic Capecitabine to Standard Adjuvant Therapy in High Risk HER2+ BC paTients

Who this might be right for
Breast Cancer
Sun Yat-sen University 794
Testing effectiveness (Phase 2)Study completedNCT00263588
What this trial is testing

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 242
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06578286
What this trial is testing

ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

Who this might be right for
Breast Cancer
Fudan University 44
Testing effectiveness (Phase 2)Looking for participantsNCT05955170
What this trial is testing

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Institut Curie 66
Large-scale testing (Phase 3)UnknownNCT03080805
What this trial is testing

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 240
Testing effectiveness (Phase 2)UnknownNCT06362096
What this trial is testing

A Multicenter, Prospective Study of Diarrhea Tolerance of Pyrotinib Combined With Trastumab and Taxane in the First-line Treatment of HER2-positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Huihua Xiong 72
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Testing effectiveness (Phase 2)Study completedNCT01816594
What this trial is testing

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Who this might be right for
HER2-positive Newly Diagnosed, Primary Breast Cancer
Novartis Pharmaceuticals 50
Testing effectiveness (Phase 2)Study completedNCT02441946
What this trial is testing

A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Breast CancerHormone Receptor Positive TumorEarly-Stage Breast Carcinoma
Eli Lilly and Company 224
Large-scale testing (Phase 3)Study completedNCT01864746
What this trial is testing

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Who this might be right for
Breast CancerHormonreceptor PositiveHer2-normal+2 more
GBG Forschungs GmbH 1,250
Early research (Phase 1)Study completedNCT03330561
What this trial is testing

PRS-343 in HER2-Positive Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Bladder Cancer+1 more
Pieris Pharmaceuticals, Inc. 85
Post-approval studies (Phase 4)Looking for participantsNCT07695259
What this trial is testing

Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer

Who this might be right for
Elderly FemalesHER2 + Breast CancerNeoadjuvant Therapy
Wen-Ming Cao 45
Testing effectiveness (Phase 2)UnknownNCT05335473
What this trial is testing

Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

Who this might be right for
HR Positive HER2 Negative Advanced Breast Cancer
Henan Cancer Hospital 87
Testing effectiveness (Phase 2)UnknownNCT05263869
What this trial is testing

MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Who this might be right for
Breast Cancer With Liver Metastases
Shanghai Miracogen Inc. 99
Large-scale testing (Phase 3)Looking for participantsNCT07518173
What this trial is testing

BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 596
Testing effectiveness (Phase 2)Looking for participantsNCT05800275
What this trial is testing

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

Who this might be right for
Leptomeningeal MetastasisLeptomeningeal DiseaseHER2-positive Metastatic Breast Cancer
UNICANCER 30
Large-scale testing (Phase 3)Looking for participantsNCT05760612
What this trial is testing

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

Who this might be right for
Early-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Large-scale testing (Phase 3)Active Not RecruitingNCT01805271
What this trial is testing

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Who this might be right for
Primary Non-metastatic Breast CancerWho Remain Disease-free
UNICANCER 1,278
Testing effectiveness (Phase 2)Study completedNCT02258451
What this trial is testing

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Bayer 283
Next Page